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Systemic Anti-TNFa Treatment Restores
Diabetes-Impaired Skin Repair in ob/ob Mice
by Inactivation of Macrophages
Itamar Goren1, Elke Mu¨ller1, Dana Schiefelbein1, Urs Christen1, Josef Pfeilschifter1, Heiko Mu¨hl1 and
Stefan Frank1
To date, diabetes-associated skin ulcerations represent a therapeutic problem of clinical importance. The
insulin-resistant type II diabetic phenotype is functionally connected to obesity in rodent models of metabolic
syndrome through the release of inflammatory mediators from adipose tissue. Here, we used the impaired
wound-healing process in obese/obese (ob/ob) mice to investigate the impact of obesity-mediated systemic
inflammation on cutaneous wound-healing processes. Systemic administration of neutralizing monoclonal
antibodies against tumor necrosis factor (TNF)a (V1q) or monocyte/macrophage-expressed EGF-like module-
containing mucin-like hormone receptor-like (Emr)-1 (F4/80) into wounded ob/ob mice at the end of acute
wound inflammation initiated a rapid and complete neo-epidermal coverage of impaired wound tissue in the
presence of a persisting diabetic phenotype. Wound closure in antibody-treated mice was paralleled by a
marked attenuation of wound inflammation. Remarkably, anti-TNFa- and anti-F4/80-treated mice exhibited a
strong reduction in circulating monocytic cells and reduced numbers of viable macrophages at the wound site.
Our data provide strong evidence that anti-TNFa therapy, widely used in chronic inflammatory diseases in
humans, might also exert effects by targeting ‘‘activated’’ TNFa-expressing macrophage subsets, and that
inactivation or depletion of misbehaving macrophages from impaired wounds might be a novel therapeutic
clue to improve healing of skin ulcers.
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INTRODUCTION
The last two decades have seen an explosive global increase
in people diagnosed with diabetes mellitus (Zimmet et al.,
2001). The diabetic skin ulceration represents an unmet
medical problem in many diabetic individuals. Diabetic
ulcers still have a poor prognosis (Apelqvist et al., 1995) and
the 3-year survival rates after limb amputations are between
50 and 59%, as assessed for Italy and Sweden, respectively
(Apelqvist et al., 1993; Faglia et al., 2001). By contrast, the
efforts to identify novel pharmacological approaches to
improve significantly severe diabetes-impaired healing con-
ditions have failed and only recombinant platelet-derived
growth factor is now available for treatment of foot ulcers
(Wiemann et al., 1998).
In the past decade, rodent models of obesity and diabetes
have been extensively used to unravel the functional
connection between an expanding adipose tissue and an
increasing insulin resistance. Initial experiments evidenced
the pro-inflammatory tumor necrosis factor (TNF)a as an
adipose tissue-derived mediator that might directly contribute
to insulin resistance in obese rodents (Hotamisligil et al.,
1993). However, recent studies now implicate bone marrow-
recruited macrophages located within adipose tissue rather
than resident adipocytes to represent the cellular source of
pro-inflammatory mediators in obesity (Weisberg et al.,
2003). Interestingly, plasma TNFa levels were also dependent
on adipose tissue mass in humans (Kern et al., 1995;
Mantzoros et al., 1997), and clinical studies confirmed that
the presence of inflammatory mediators predicts the devel-
opment of type II diabetes mellitus (Schmidt et al., 1999;
Pradhan et al., 2001).
Here, we used the obese/obese (ob/ob) mouse as a model
system of impaired wound healing. These mice are char-
acterized by severe diabetes and obesity syndromes (Cole-
man, 1978). The diseased phenotype is mediated by the
functional loss of the ob gene product: the 16 kDa cytokine
leptin (Zhang et al., 1994). Leptin is now well established as
an adipocytokine, which is secreted from adipocytes and
functions in the regulation of neuroendocrine circuits, energy
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homeostasis, and as an important mediator of immune-
mediated diseases and inflammatory processes (Tilg and
Moschen, 2006). Systemic leptin administration into
wounded ob/ob mice led to the resolution of the diabetic
phenotype and improved the severely disturbed healing
conditions by acting as a mitogen for wound keratinocytes,
attenuating the inflammatory wound response and restoring
insulin signaling in wound tissue (Frank et al., 2000; Goren
et al., 2003, 2006).
Interestingly, also systemic application of an anti-TNFa
antibody markedly increased insulin receptor expression in
wound tissue (Goren et al., 2006). These recent findings
strongly suggest a possible functional connection between
adipose tissue-derived TNFa and wound-healing disorders in
ob/ob mice, although the mechanism still remains unknown.
TNFa is a major product of classically activated macrophages
(Gordon, 2002; Mosser, 2003); however, it must not
necessarily be secreted. TNFa is synthesized as a membrane
protein, which can be cleaved by TNFa-converting enzyme
to allow the subsequent release of the cytokine from activated
macrophages (Solomon et al., 1999).
In this study, we provide strong evidence that improved
skin repair in diabetic and obese mice after systemic
administration of a TNFa-neutralizing antibody was function-
ally connected to markedly reduced monocyte/macrophage
numbers in ob/ob mice. Thus, our data strongly suggest that
impaired wound-healing conditions in ob/ob mice were
driven by TNFa-expressing macrophages, which occurred as
a consequence of metabolic disorders in the animals.
Moreover, our findings prove a beneficial effect of a TNFa
neutralization strategy in impaired wound healing, which
was mediated by a yet unknown induction of cell death of
activated macrophages in disturbed wound tissue, and thus
extend its therapeutic potential beyond the treatment of
chronic inflammatory diseases.
RESULTS
Short-term anti-TNFa (V1q) and anti-macrophage (F4/80)
treatments did not improve metabolic syndrome in wounded
ob/ob mice
Adipose tissue-derived TNFa is considered to be functionally
involved in obesity-associated insulin resistance (Hotamisligil
et al., 1993; Wellen and Hotamisligil, 2005). To elucidate the
potential mechanism of obesity-related TNFa interference
with skin repair in ob/ob mice (Goren et al., 2006), we first
analyzed circulating levels of TNFa in serum of the animals.
To this end, we injected a monoclonal antibody against
murine TNFa (V1q) (Echtenacher et al., 1990) into wounded
ob/ob mice. However, we had to avoid any interference with
physiologic functions of normally expressed TNFa during the
acute phase of skin repair (Figure 1a), as we intended to
restrictively interfere only with a potential pathophysiological
role of TNFa during diabetes-impaired wound-healing con-
ditions. To reach this goal, we administered the rat
monoclonal V1q antibody at days 7, 9, and 11 upon injury
by intraperitoneal injection. Specific antibody treatment was
controlled by intraperitoneal administration of a nonspecific
rat IgG at days 7, 9, and 11 after wounding. Consistent with
published data (Hotamisligil et al., 1993), we found low
levels of TNFa in the sera of ob/ob mice and V1q treatment
did not reduce circulating TNFa (Figure 1b). Even a 16-day
systemic leptin treatment of the mice, which served as control
for correction of the metabolically disturbed phenotype
(Figure 1c–e) and impaired healing in ob/ob mice (Pelley-
mounter et al., 1995; Frank et al., 2000; Ring et al., 2000;
Goren et al., 2003, 2006), did not reduce serum TNFa levels
(Figure 1b). In clear contrast to unaltered TNFa levels upon
antibody or leptin regimens, we could observe a dramatic
improvement of wound morphology in leptin- and TNFa-
treated animals compared to the IgG-administered control
group (Figure 2). One possibility to explain the discrepancy
between unchanged circulating TNFa levels and improved
skin repair might arise from binding of V1q to membrane-
bound TNFa in monocytes/macrophages (Solomon et al.,
1999; Lu¨gering et al., 2001) with a subsequent depletion of
the cells by induction of apoptosis and/or complement
activation (Nauta et al., 2002). To experimentally mimic this
condition in the mice, we included the monocyte/macro-
phage-specific F4/80 rat monoclonal antibody (Austyn and
Gordon, 1981; Hirsch et al., 1981) into our experimental
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Figure 1. Anti-TNFa (V1q) and anti-macrophage (F4/80) treatments did not
improve the metabolic syndrome in ob/ob mice. (a) RNase protection assay
demonstrating TNFa mRNA expression in non-wounded back skin (ctrl skin)
and wound tissue isolated from C57Bl/6 and ob/ob mice. The time after injury
is indicated for each lane. Levels of TNFa (b) and insulin (c) in serum, blood
glucose (d), and body weight (e) in ob/ob mice at day 13 after wounding.
Mice had been treated with leptin (starting at 2 days before wounding, one
application per day), V1q- and F4/80-specific rat monoclonal antibodies or a
nonspecific rat IgG (injections at days 7, 9, and 11 post-wounding for the
antibody treatment). **Po0.01; *Po0.05 vs IgG-treated animals. Bars
indicate the mean7SD obtained from four individual animals (n¼ 4).
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setup by systemic application at days 7, 9, and 11 upon
wounding. Both the V1q and F4/80 antibodies did not
significantly improve the disturbed metabolic phenotype of
ob/ob mice, as the animals remained severely hyperinsulin-
emic (Figure 1c), hyperglycemic (Figure 1d), and obese
(Figure 1e).
Short-term systemic anti-TNFa (V1q) and anti-macrophage
(F4/80) treatments strongly improved healing of chronic
wounds in ob/ob mice with persisting metabolic syndrome
Most remarkably, we observed a profound improvement of
impaired wound tissue in response to the administration of
the V1q or F4/80 antibodies. Here, it is important to note that
changes in chronic wounds toward a properly healing wound
area occurred within 6 days, as we applied the V1q, F4/80, or
the nonspecific control antibodies only three times from day
7 after wounding and subsequently analyzed wound mor-
phology as early as day 13 after wounding. As shown in
Figure 2, anti-TNFa (V1q) or anti-monocyte/-macrophage (F4/
80) treatments resulted in a general resolution of chronic
wound conditions in the animals. We found a significant
reduction of persisting scabs on the backs of antibody-treated
animals (Figure 2a, left panel). This parameter served as an
initial readout for wound epithelialization, as scabs are lost
after formation of a robust neo-epidermal coverage of the
wound site. In parallel, wound areas were also significantly
reduced by antibody treatment (Figure 2a, right panel). Leptin
administration of animals, starting at day 2 before wounding,
is well established to mediate a robust improvement of
impaired wounds in ob/ob mice (Frank et al., 2000; Ring
et al., 2000; Goren et al., 2003, 2006). The above-mentioned
improved wound-healing conditions upon leptin, V1q, and
F4/80 applications (Figure 2a) are documented by photo-
graphs of representative animals shown in Figure 2b. As a
next step, we performed a histological analysis of wound
tissue from the different experimental settings. First, we
observed a poor tissue regeneration in IgG-treated control
mice and wound areas were characterized by atrophied
wound margin epithelia. Additionally, the granulation tissue
appeared to be reduced (Figure 2c, IgG panel). By contrast,
systemic leptin administration, which exerts its actions in
functional connection to the resolution of the diabetic
phenotype (Figure 1c–e), mediated an improvement of wound
morphology as assessed by the formation of both a robust
multilayered neo-epithelium and a dense neo-dermis (Figure
2c, lep panel). Although effects on wound morphology
appeared to be not as pronounced compared to leptin
treatment, both V1q and F4/80 antibody administrations
mediated the formation of an epithelial coverage of the
wound area, which was paralleled by the formation of a
dense neo-dermis. Thus, treatment strategies using the
antibodies were able to drive a rapid formation of an
epithelial coverage onto chronic wounds in the presence of
persisting hyperglycemia and, thus, a diabetic phenotype in
the mice (Figure 1c–e).
Short-term anti-TNFa (V1q) or anti-macrophage (F4/80)
treatments markedly attenuated wound inflammatory
conditions
Leptin-driven skin repair in ob/ob mice was associated with a
marked decline in wound inflammation following the acute
phase of repair, whereas chronic healing conditions exhibited
a sustained inflammatory response in ob/ob as well as db/db
mice (Wetzler et al., 2000; Goren et al., 2003). Thus, it was
interesting to investigate the inflammatory status of V1q- or
F4/80-improved wound tissue in ob/ob mice. We observed a
strong attenuation of the inflammatory response at the wound
site upon targeting both the TNFa or macrophage-specific
antigens in the mice (Figure 3). IL-b, TNFa, or cyclooxygen-
ase (COX)-2 mRNA levels were significantly reduced upon
systemic antibody application. However, chemokine (C-C
motif) ligand 2 (CCL2) mRNA expression at the wound site
was much less influenced by the treatments (Figure 3a).
Nevertheless, we found a clear reduction of IL-1b, TNFa, and
CCL2 proteins in healing-improved wound tissue isolated
from leptin-, V1q-, and F4/80-treated mice (Figure 3b). These
data provide strong evidence that the beneficial effects of
both antibodies in disturbed healing are functionally linked to
the reduction of exacerbated wound inflammatory conditions
in obese and diabetic mice.
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Figure 2. Analysis of wound morphology. (a) Presence of scab-covered
wounds and wound area of 13 day wounds in IgG-, leptin-, V1q-, and
F4/80-treated ob/ob mice. **Po0.01 versus IgG-treated animals. ##Po0.01
as indicated by the brackets. Bars indicate the mean7SD from 24 wounds
(n¼24) from four individual animals (n¼4). (b) photographs of 13-day
back skin wounds in IgG-, leptin-, V1q-, and F4/80-treated ob/ob mice.
(c) Representative histological analyses of 13 day wound tissue isolated from
individual IgG-, leptin-, V1q-, and F4/80-treated ob/ob mice as indicated.
Formalin-fixed, paraffin-embedded 6 mm sections were counterstained using
eosin/hematoxylin. Abbreviations: at, adipose tissue; gt, granulation tissue;
gt*, atrophied gt; nd, neo-dermis; ne, neo-epidermis, sc, scab. Bar¼ 1 mm.
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Short-term anti-TNFa (V1q) or anti-macrophage (F4/80)
treatments reduced circulating monocytes and resident wound
macrophage numbers
Here, we hypothesized a similar mode of action for V1q and
F4/80 in ob/ob mice in vivo via a potential depletion of
macrophages by complement activation. Indeed, both anti-
bodies mediated an accelerated skin repair and an attenuated
wound inflammation in ob/ob mice in the presence of a
severe diabetic phenotype. To strengthen our hypothesis, we
focused our investigations on the monocyte/macrophage cell
type as the potential target cell to explain the effects of
both applied antibody strategies. First, we determined the
impact of systemic application of leptin, V1q, and F4/80 on
circulating monocyte numbers. FACS analysis using a PE-
coupled F4/80 antibody determined circulating monocytes to
represent a 13.473.1% fraction as compared to the total
leukocyte count (Figure 4). Interestingly, leptin did not
significantly change numbers of circulating monocytes. By
contrast, FACS analysis revealed a dramatic loss (about 80%)
of monocytic cell numbers in the circulation of ob/ob mice
upon treatment with either V1q or F4/80 antibodies (Figure 4).
Loss of monocytic cells was profound and resulted in
remaining monocytic fractions of 3.771.0% for V1q or
2.570.3% for F4/80 treatment, respectively. These data
provided strong experimental evidence that both antibodies,
which were not functionally related with respect to their
antigenic target molecule, exhibited their therapeutic poten-
tial by targeting the identical cell type. Moreover, subsequent
analysis of wound macrophage numbers translated our
antibody-mediated effects from the circulation into the poorly
regenerating peripheral wound tissue. As shown in Figure 5a,
improved wound tissue isolated from V1q- and F4/80-treated
ob/ob mice exhibited a reduction in wound macrophage
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Figure 3. V1q and F4/80 attenuate wound inflammation in impaired wounds of ob/ob mice. Mice had been treated with a nonspecific IgG or leptin
(starting at 2 days before wounding, one application per day), or V1q and F4/80 (injections at days 7, 9, and 11 after wounding). (a) IL-1b, TNFa, COX-2,
and CCL2 mRNA expression in 13-day wound tissue isolated from IgG-, leptin-, V1q-, and F4/80-treated ob/ob mice as indicated. #1–3 represent individual
animals. For the RNase protection assay (left panels), every experimental time point depicts three wounds (n¼ 3) isolated from a single individual mouse.
A glyceraldehyde-3-phosphate dehydrogenase hybridization is shown as a loading control. 1,000 cpm of the hybridization probe were used as a size marker.
Statistical analysis of IL-1b, TNFa, COX-2 and CCL2 mRNA expression is shown in the right panels. **Po0.01; *Po0.05 vs IgG-treated animals. #Po0.05
as indicated by the brackets. Bars indicate the mean7SD from 12 wounds (n¼ 12) from four individual animals (n¼4). (b) IL-1b-, TNFa-, and CCL2-specific
ELISA analyses from 13-day wound lysates isolated from IgG-, leptin-, V1q-, and F4/80-treated ob/ob mice as indicated. **Po0.01; *Po0.05 versus
IgG-treated animals. ##Po0.01; NS, not significant as indicated by the brackets. Bars indicate the mean7SD from eight wounds (n¼ 8) from four individual
animals (n¼ 4).
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Figure 4. Determination of circulating F4/80-positive monocytes in ob/ob
mice. Mice had been treated with a nonspecific IgG or leptin (starting at 2
days before wounding, one application per day), or V1q and F4/80 (injections
at days 7, 9, and 11 after wounding). At day 13 after wounding, fresh blood
from IgG-, leptin-, V1q-, and F4/80-treated ob/ob mice was analyzed for
F4/80-positive monocytes by FACS analysis as indicated. **Po0.01 versus
IgG-treated animals. Bars indicate the mean7SD from four individual
animals (n¼ 4).
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numbers. A quantitative analysis of constitutively expressed
macrophage-specific lysozyme M and Emr-1 mRNA species
in wound tissue (Figure 5a) and the immunohistological
staining for F4/80-positive cells (Figure 5b) both demons-
trated an approximately 50–60% reduction of wound macro-
phages in V1q- and F4/80-improved healing conditions. In
contrast to both antibody treatments, these data suggested a
different mode of action for leptin to improve repair in ob/ob
mice, as the remaining high numbers of wound macrophages
did not drive an exacerbated wound inflammation, but
appeared to be silenced as a direct consequence of leptin
action (Figure 3).
Short-term anti-TNFa (V1q) or anti-macrophage (F4/80)
treatments triggered apoptosis of wound macrophages
As we had observed a strong depletion of monocytes from the
circulation after V1q and F4/80 treatments, which were
related to reduced numbers of wound macrophages, we were
finally interested in infiltrating macrophage conditions in the
context of the applied diverse treatment regimens and tissue
environments. To this end, we performed a terminal
deoxyribonucleotidyl transferase-mediated biotin-16-dUTP
nick-end labeling (TUNEL) assay in a double-labeling
experiment, which allowed us a simultaneous detection of
F4/80- and TUNEL-positive apoptotic cells within different
wound tissues. Interestingly, we observed the lowest percent-
age of TUNEL-positive and thus apoptotic macrophages in
wounds isolated from phosphate-buffered saline, as well as
leptin-treated ob/ob mice (Figure 6a–c). Impaired wounds in
IgG-treated animals were thus characterized by high numbers
of viable macrophages (Figure 6a–c), which most probably
triggered an augmented and sustained inflammatory response
at the wound site (Figure 3) that obviously interfered with
repair (Figure 2). By contrast, high numbers of viable wound
macrophages upon leptin administration here indeed sug-
gested that leptin did not exert its beneficial effects on skin
repair by interfering with monocyte viability (Figures 4 and 6)
but through downregulation of wound macrophage inflam-
matory responses (Figure 3). More importantly, wound tissue
from V1q- and F4/80-treated ob/ob mice was characterized
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by highest numbers of apoptotic and thus non-viable
macrophages (Figure 6a–c). Interestingly, immunohistological
staining for processed and thus active caspase-3 strongly
suggested that systemic antibody treatments exerted its
actions via induction of a controlled macrophage cell death.
These data show that nearly all (more than 80%) infiltrating
macrophages that were reduced in number upon V1q
and F4/80 applications additionally appeared to be in an
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Figure 6. Wound macrophages in V1q- and F4/80-treated ob/ob mice are in an apoptotic state. (a) Paraffin-fixed sections (6mm) of 13-day wound granulation
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showing the calculated number of viable macrophages in 13-day wound sections from IgG-, leptin-, V1q-, and F4/80-treated ob/ob mice as indicated.
(c) Paraffin-fixed sections (6 mm) of 13-day wound granulation tissue isolated from IgG-, leptin-, V1q-, and F4/80-treated ob/ob mice as indicated were
simultaneously stained for macrophage-specific F4/80 (red) and apoptotic cells by TUNEL (brown) using a peroxidase-based technique. TUNEL-positive
macrophages are indicated. Bar¼40 mm. (d) Granulation tissue (13-day wounds) from IgG-, V1q-, and F4/80-treated ob/ob mice as indicated was analyzed for
macrophage-specific F4/80 (red) and processed active caspase-3 (brown). F4/80 and active caspase-3 double-positive macrophages are indicated. Bar¼ 30 mm.
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apoptotic state, and thus were no longer able to interfere with
skin repair even under severe diabetic conditions in the
animals.
DISCUSSION
A series of wound-healing experiments performed by
Leibovich and Ross (1975) in the 1970s established a prime
role of activated macrophages in skin repair. These ‘‘classi-
cal’’ studies using a guinea pig wound model demonstrated
that depletion of macrophages under sterile conditions
resulted in the failure of animals to clear wound tissue of
matrix, dead and damaged cells, fibrin, and debris (Leibovich
and Ross, 1975). In a recent review, Leibovich questioned his
early statement that ‘‘it has largely been considered taboo to
tinker too heavily with the inflammatory response at the
wound site for fear of aborting this process’’ (Martin and
Leibovich, 2005). Indeed, observations from chronic wound-
healing conditions in humans, as well as mice, strongly
support the wound macrophage to interfere with the normal
repair process under conditions of impaired healing. It is
known that macrophage numbers are markedly elevated in
human chronic leg ulcers (Rosner et al., 1995; Loots et al.,
1998) and in chronic wounds of genetically diabetic and
obese db/db and ob/ob mouse models (Wetzler et al., 2000;
Goren et al., 2003). Nevertheless, although the presence of
elevated macrophage numbers at chronic wound sites
strongly suggested a key role of this cell type in the control
and orchestration of pathobiology in impaired wound tissue,
most of the experimental work in the field restrictively
focused on the role of soluble mediators. Not unexpected, an
aberrant expression of diverse protein-type mediators has
been reported in disturbed healing conditions in a series of
animal studies (for a review see Werner and Grose, 2003).
Unfortunately, however, therapeutic approaches to improve
disturbed wound healing in humans and mice by exogenous
administration of missing or dysregulated factors by applica-
tion of single recombinant protein mediators have failed
(Jeffcoate and Harding, 2003).
Obviously, resident cells in diabetic ulcers are phenoty-
pically altered with respect to their sensitivity toward
exogenous signals (Falanga, 2005; Goren et al., 2006). Thus,
it is reasonable to argue that a yet poorly understood
mechanism drives a complex dysregulation of inter- and
intracellular signaling machineries that normally enable the
proper and accurate communication of resident cells
embedded into healing wound tissue and thus causes the
failure to pharmacologically correct wound-healing disorders
through application of recombinant mediators. Interestingly,
one such underlying mechanism might emerge from studies
using obese and diabetic rodents. TNFa is now discussed as a
pivotal mediator connecting obesity and insulin resistance
(Hotamisligil et al., 1993), but low levels of free-circulating
serum TNFa even in obese mice suggested a different mode
of action for the therapeutically applied anti-TNFa antibody.
Recent studies implicated macrophages rather than adipo-
cytes as the cellular source of obesity-associated TNFa that is
functionally connected to conditions of insulin resistance.
Adipose tissue macrophages were bone marrow-derived,
recruited via chemokine (C-C motif) receptor 2 activation,
and most likely responsible for adipose tissue-derived TNFa
production in obese mice (Weisberg et al., 2003, 2006).
Macrophages must be in an activated state to produce
TNFa (Gordon, 2002; Mosser, 2003). As TNFa did not appear
in high levels in the circulation of obese mice (Hotamisligil
et al., 1993; this study), it is tempting to argue that TNFa
might not be released from activated macrophages during
developing obesity to mediate conditions of increasing
insulin resistance. This notion is strongly supported by
observations that inflammatory stimuli induced a mem-
brane-bound form of TNFa in monocytes or macrophages,
which might be subsequently released by TNFa-converting
enzyme cleavage under inflammatory conditions (Solomon
et al., 1999). Moreover, data from our study provide evidence
that obesity-related disturbances might be mediated by a
central pool of circulating TNFa-positive monocytes from
which mononuclear cells enter diverse organ systems.
Obviously, anti-TNFa treatment of ob/ob mice depleted these
activated monocytes from the circulation and caused a
marked reduction of macrophage numbers in disturbed
wound sites in the animals. More importantly, depletion of
circulating and wound monocytic cells in ob/ob mice
resulted in a rapid and profound transformation of chronic
wounds into healing skin tissue.
Additionally, our data demonstrate that the obesity-
changed macrophage cell type itself and not the action of
an obesity-induced TNFa molecule is in the center of
disturbed skin repair in diabetes. Thus, TNFa neutralization
using systemically applied antibodies has to be regarded as
an epiphenomenon with respect to the observed beneficial
effects of the anti-TNFa therapy on impaired wound healing,
as we obtained a comparable effect with respect to
circulating monocyte numbers and improval of skin repair
using an antibody directed against the monocyte/macro-
phage-specific membrane protein F4/80 (Austyn and Gordon,
1981; Hirsch et al., 1981). Therefore, the mode of action of
infliximab, a TNFa-neutralizing antibody used for therapy of
chronic inflammatory diseases in humans, might be more
diverse with respect to its TNFa-binding properties than
initially expected. This hypothesis is strongly supported by
the work of Lu¨gering et al. (2001), who reported a marked
induction of apoptosis in circulating monocytes by infliximab
in patients with Crohn’s disease. In accordance, our V1q and
F4/80 treatments of wounded diabetic mice also targeted
obesity-activated monocytes in the circulation by reducing
their total numbers. Moreover, the remaining monocytes that
had actually escaped this process and reached the chronified
wound tissue were obviously in an apoptotic state and could
no longer interfere with the healing process. These findings
are strongly supported by the potency of the anti-TNFa
antibodies infliximab and adalumimab, but not the soluble
receptor etanercept, to selectively mediate caspase-depen-
dent apoptosis in cultured human monocytes, a process
that is paralleled by a marked decrease in cytokine release
from the cells (Shen et al., 2005, 2006). In summary, our
observations indicate a pivotal role for activated macro-
phages in the development of diabetes-impaired wound
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healing and strongly suggest a pharmacologic targeting of
those activated macrophages as a promising therapeutic
approach to improve impaired wound-healing conditions in
general.
MATERIALS AND METHODS
Animals
Female C57Bl/6 and C57BL/6J-ob/ob mice were obtained from The
Jackson Laboratories (Bar Harbor, ME) and maintained under a 12 h
light/12 h dark cycle at 221C until they were 8 weeks of age. At this
time, they were caged individually, monitored for body weight and
wounded as described below.
Treatment of mice
Murine recombinant leptin (Calbiochem, Bad Soden, Germany) was
injected intraperitoneally (2mg/g body weight, one injection per day,
from 2 days before wounding until day 13 after wounding) and
purified rat monoclonal antibodies directed against TNFa (V1q)
(Echtenacher et al., 1990) (Abcam Ltd, Cambridge, UK), F4/80
(Austyn and Gordon, 1981; Hirsch et al., 1981) (SeroTec, Du¨sseldorf,
Germany), or a nonspecific rat IgG (Santa Cruz, Heidelberg,
Germany) were injected intraperitoneally (1mg/g body weight) in
0.5 ml phosphate-buffered saline at days 7, 9, and 11 after injury.
Wounding of mice
Wounding of mice was performed as described previously
(Frank et al., 1999; Stallmeyer et al., 1999). Briefly, mice were
anesthetized and six full-thickness wounds (5 mm in diameter,
3–4 mm apart) were made on the back of each mouse. An area of
7–8 mm in diameter was excised at the indicated time points for
analysis. As a control, a similar amount of skin was taken from the
backs of non-wounded mice. For each experimental time point,
tissue from four wounds each from four animals (n¼ 16 wounds,
RNA analysis) and from two wounds each from four animals (n¼ 8
wounds, protein analysis) were combined and used for RNA and
protein preparation. All animal experiments were carried out
according to the guidelines and were approved by the local Ethics
Animal Review Board.
RNA isolation and RNase protection analysis
RNA isolation and RNase protection assays were carried out as
described previously (Chomczynski and Sacchi, 1987; Frank et al.,
1999). The cDNA probes were cloned using RT-PCR. The probes
corresponded to nt 481–739 (for IL-1b, NM008361), nt 541–814 (for
TNFa, NM013693), nt 796–1063 (for COX-2, M64291), nt 623–323
(for CCL2, NM011333), nt 23–296 (for lysozyme M, BC002069), nt
2561–2845 (for Emr-1, X93328), and nt 163–317 (for glyceralde-
hyde-3-phosphate dehydrogenase, NM002046) of the published
sequences.
Immunohistochemistry
Mice were wounded as described above. Animals were killed at day
13 after injury. Complete wounds were isolated from the back and
fixed in formalin. Bisected wounds were embedded in paraffin.
Immunohistochemistry from 6 mm deparaffinized sections was
performed as described (Stallmeyer et al., 1999). The monoclonal
antibody directed against macrophage-specific F4/80 antigen was
from Serotec, Du¨sseldorf, Germany. The anti-active caspase-3
antibody was obtained from Innovative Diagnostik Systeme
(Hamburg, Germany).
Determination of apoptotic macrophages in wound tissue by
TUNEL staining
Isolated 13 day wound tissue from ob/ob mice was fixed according
to the HOPE (Hepes glutamic acid buffer mediated organic solvent
protection effect) method and subsequently embedded in low-
melting paraffin (Innovative Diagnostik Systeme, Hamburg, Ger-
many). Sections (6mm) of HOPE-fixed wound tissue was stained for
apoptotic cells using the fluorescence-based dead end calorimetric
TUNEL system (Promega, Mannheim, Germany) or the peroxidase-
based ApopTag peroxidase in situ apoptosis detection kit (Chemi-
con, Millipore, Schwalbach, Germany) according to the instructions
of the manufacturer. Sections were subsequently incubated with
macrophage-specific rhodamine-coupled F4/80 antibody (1:200
dilution, Serotec). Nuclei were counterstained using 4,6-diamidi-
no-2-phenylindole staining (Sigma, Deisenhofen, Germany).
Flow cytometry
Two hundred microliter whole blood of ob/ob mice was mixed with
5 ml RBC lysis buffer (0.74% NH4Cl) and incubated for 30 minutes to
lyse red blood cells. The remaining leukocytes were washed, plated at
105 cells/well and incubated with 50ml phycoerythrin-conjugated
anti-F4/80 antibody (BD Biosciences, Heidelberg, Germany) (1:100
diluted in phosphate-buffered saline containing 1% fetal calf serum)
for 30 minutes at 41C. Cells were washed and analyzed for surface F4/
80 expression using a FACSCalibur flow cytometer (BD Biosciences).
ELISA
Total wound lysate (25 mg), from 13 day wounds, was analyzed for
the presence of immunoreactive IL-1b, TNFa, or CCL2 by ELISA
using the respective Quantikine murine ELISA kits (R&D systems,
Wiesbaden, Germany).
Determination of blood glucose and blood insulin levels
Blood glucose levels were determined using the Accutrend sensor
(Roche Biochemicals, Mannheim, Germany) and serum insulin was
analyzed by ELISA (Crystal Chemicals, Chicago) as described by the
manufacturer.
Statistical analysis
Data are shown as means7SD. Data analysis was carried out using
the unpaired Student’s t-test with raw data.
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